Discontinued — last reported Q1 '24
Impairment Charges
Year-over-year, this metric declined by 58.7%, from $264.00M to $109.00M. This is a positive signal — lower values indicate better performance for this metric.
Analysis
How to read this metric
An increase signals poor past investment decisions or deteriorating market conditions, which is generally viewed negatively by investors.
Detailed definition
These are non-cash charges recognized when the carrying value of an asset exceeds its fair market value. Such charges in...
Peer comparison
Common in large, diversified firms that frequently acquire or divest business units.
impairment_chargesHistorical Data
| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q1 '24 | |
|---|---|---|---|---|---|---|---|---|
| Value | $2.00M | $0.00 | $0.00 | $0.00 | $200.00M | $264.00M | $0.00 | $109.00M |
| QoQ Change | — | -100.0% | — | — | — | +32.0% | -100.0% | — |
| YoY Change | — | — | — | -100.0% | — | — | — | -58.7% |
Product Breakdown
| Segment | Q3 '23 | Q1 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 |
|---|---|---|---|---|---|---|---|---|
| Tukysa | — | — | — | $400.00M | $205.00M | $205.00M | $205.00M | $205.00M |
| disitamab vedotin | — | $50.00M | $50.00M | — | — | $400.00M | — | — |
| Etrasimod (Velsipity) | $350.00M | — | — | — | — | — | — | — |
| Prevnar 13 | $241.00M | — | — | — | — | — | — | — |
| Prevnar 13 - Adult | $32.50M | — | — | — | — | — | — | — |
| Prevnar 13 - Pediatric | $208.50M | — | — | — | — | — | — | — |
| Total | — | $109.00M | — | — | — | — | — | — |
disitamab vedotin, Etrasimod (Velsipity), osivelotor, Prevnar 13, Prevnar 13 - Adult, Prevnar 13 - Pediatric are derived from annual filings.
Business Segments
| Segment | Q1 '23 | Q4 '23 | Q2 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 |
|---|---|---|---|---|---|---|---|---|
| Biopharma | $128.00M | $2.80B | $240.00M | $2.90B | $210.00M | $0.00 | $260.00M | $3.64B |
| Total | $264.00M | — | — | — | — | — | — | — |
Biopharma was previously reported and has since been discontinued or reclassified. Only currently active segments are shown in the chart.
Impairment Charges at Other Companies
Frequently Asked Questions
- What is Pfizer's impairment charges?
- Pfizer (PFE) reported impairment charges of $109.00M in Q1 2024.
- How has Pfizer's impairment charges changed year-over-year?
- Pfizer's impairment charges decreased by 58.7% year-over-year, from $264.00M to $109.00M.
- What does impairment charges mean?
- A write-down of the value of assets that are no longer worth what they are listed for.